• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
【24h】

Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

机译：Ustekinumab和依那西普治疗牛皮癣的疗效和安全性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IMPORTANCE OF THE FIELD: TNF-alpha inhibitors such as etanercept have been used for psoriasis for years. A fairly well defined efficacy and safety profile has developed. A new biologic agent, ustekinumab, an IL-12 and IL-23 inhibitor, has recently been released in the US for the treatment of moderate-to-severe psoriasis. The purpose of this article is to compare the efficacy and safety profiles of ustekinumab and etanercept. AREAS COVERED IN THIS REVIEW: We examined safety and efficacy data regarding ustekinumab and etanercept from clinical reports, a head-to-head trial, review articles, and databases and registries from the last 20 years. WHAT THE READER WILL GAIN: Evidence is reviewed about the efficacy for the treatment of psoriasis as well as the safety profiles for both agents, ustekinumab and etanercept. TAKE HOME MESSAGE: Both drugs have data to confirm efficacy and safety in patients with moderate-to-severe psoriasis in the short-term. The limited long-term data on the safety profile of ustekinumab requires careful judgment on the clinician's part, weighing well-defined benefits and potential unknown risks.
机译：领域的重要性：TNF-α抑制剂如依那西普已用于牛皮癣多年。已经开发了相当明确的功效和安全性概况。一种新的生物制剂，乌斯他单抗，一种IL-12和IL-23抑制剂，最近已在美国发布，用于治疗中度至重度牛皮癣。本文的目的是比较ustekinumab和etanercept的疗效和安全性。该评价涵盖的区域：我们检查了最近20年来临床报告，针刺试验，评价文章以及数据库和注册表中有关优特珠单抗和依那西普的安全性和有效性数据。读者的收获：审查了有关治疗牛皮癣的功效以及乌斯他单抗和依那西普这两种药物的安全性的证据。温馨提示：两种药物都有数据可在短期内确认中度至重度牛皮癣患者的疗效和安全性。关于ustekinumab安全性的长期数据有限，需要临床医生仔细判断，权衡明确定义的益处和潜在的未知风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号